CiMaas validates new methodology for feeder cells expansion
Feeder cells play a critical role in enabling robust proliferation and activation of NK cells during ex vivo manufacturing. A […]
Uncategorized
News
CiMaas obtained another grant from LIOF for validation of its feeder cell technology
CiMaas receives a new grant from LIOF to further explore the recently developed and patented feeder cell technology. A GMP
News
CiMaas moves into new facility
As of today, CiMaas is located at the Schleperweg 36, in Maastricht (NL). In this facility we continue our work
News
CiMaas cell therapy programs for treatment of patients with cancer gets a new boost
Thanks to an investment from 819 Evergreen Fund I, we are pleased to be able to continue working on our
News
CiMaas and CYTEA BIO are pleased to announce their collaboration on Natural Killer cells
Under the agreement, CiMaas will provide CYTEA BIO with the GMP-grade K562-F012 feeder cells for the expansion of its umbilical
News
CiMaas receives EMA qualification for NK cell product
The Committee for Advanced Therapies (CAT) from the European Medicine Agency (EMA) has classified the NK cell technology developed by CiMaas as somatic cell
News
EU grants Seal of Excellence to CiMaas
Recently 1085 companies were invited to submit a full proposal – based on a first screening – to apply for
News
CiMaas improved large scale NK cell expansion using its newly developed feeder cell technology
Upon rigorous analysis, our research has demonstrated that this innovative feeder cell approach results in an enhanced proliferation rate for
News
Combotope Therapeutics and CiMaas Announce Oncology Research and License Option Agreement
Collaboration for the discovery and development of innovative cancer-specific CAR-NK products is underway, leveraging Combotope Therapeutics’ proprietary Tumor Glycoform specific